Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIIa trial of heterologous booster SARS-CoV-2 variant mRNA vaccine after prior inactivated COVID-19 vaccination
ChiCTR2200065736Phase 3Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- Nov 2022
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of SARS-CoV-2 variants mRNA vaccine and recombinant COVID-19 (XBB) trimer protein vaccine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by The First Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Live virus neutralizing antibody titers against SARS-CoV-2 current major endemic strain. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
SARS-CoV-2 variants mRNA vaccinerecombinant COVID-19 (XBB) trimer protein vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2200065736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065736.